188 related articles for article (PubMed ID: 26176707)
1. RAC1 P29S regulates PD-L1 expression in melanoma.
Vu HL; Rosenbaum S; Purwin TJ; Davies MA; Aplin AE
Pigment Cell Melanoma Res; 2015 Sep; 28(5):590-8. PubMed ID: 26176707
[TBL] [Abstract][Full Text] [Related]
2. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
3. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
Oncogene; 2024 Mar; 43(10):729-743. PubMed ID: 38243078
[TBL] [Abstract][Full Text] [Related]
4. Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.
Araiza-Olivera D; Feng Y; Semenova G; Prudnikova TY; Rhodes J; Chernoff J
Oncogene; 2018 Feb; 37(7):944-952. PubMed ID: 29059171
[TBL] [Abstract][Full Text] [Related]
5. RAC1
Lionarons DA; Hancock DC; Rana S; East P; Moore C; Murillo MM; Carvalho J; Spencer-Dene B; Herbert E; Stamp G; Damry D; Calado DP; Rosewell I; Fritsch R; Neubig RR; Molina-Arcas M; Downward J
Cancer Cell; 2019 Jul; 36(1):68-83.e9. PubMed ID: 31257073
[TBL] [Abstract][Full Text] [Related]
6. RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.
Foth M; Parkman G; Battistone B; McMahon M
Pigment Cell Melanoma Res; 2020 Sep; 33(5):719-730. PubMed ID: 32406574
[TBL] [Abstract][Full Text] [Related]
7. Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.
Tarhini AA; Zahoor H; Yearley JH; Gibson C; Rahman Z; Dubner R; Rao UN; Sander C; Kirkwood JM
J Transl Med; 2015 Sep; 13():319. PubMed ID: 26419843
[TBL] [Abstract][Full Text] [Related]
8. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
Watson IR; Li L; Cabeceiras PK; Mahdavi M; Gutschner T; Genovese G; Wang G; Fang Z; Tepper JM; Stemke-Hale K; Tsai KY; Davies MA; Mills GB; Chin L
Cancer Res; 2014 Sep; 74(17):4845-4852. PubMed ID: 25056119
[TBL] [Abstract][Full Text] [Related]
9. DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1
Tomino T; Tajiri H; Tatsuguchi T; Shirai T; Oisaki K; Matsunaga S; Sanematsu F; Sakata D; Yoshizumi T; Maehara Y; Kanai M; Cote JF; Fukui Y; Uruno T
Biochem Biophys Res Commun; 2018 Feb; 497(1):298-304. PubMed ID: 29432733
[TBL] [Abstract][Full Text] [Related]
10. Unique vulnerability of
Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
bioRxiv; 2023 Jun; ():. PubMed ID: 37425776
[No Abstract] [Full Text] [Related]
11. Enhanced Dendritic Actin Network Formation in Extended Lamellipodia Drives Proliferation in Growth-Challenged Rac1
Mohan AS; Dean KM; Isogai T; Kasitinon SY; Murali VS; Roudot P; Groisman A; Reed DK; Welf ES; Han SJ; Noh J; Danuser G
Dev Cell; 2019 May; 49(3):444-460.e9. PubMed ID: 31063759
[TBL] [Abstract][Full Text] [Related]
12. Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
Yoshikawa S; Kiyohara Y; Otsuka M; Kondou R; Nonomura C; Miyata H; Iizuka A; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Sugino T; Mochizuki T; Yamaguchi K; Akiyama Y
Anticancer Res; 2017 Mar; 37(3):1321-1328. PubMed ID: 28314298
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Madore J; Vilain RE; Menzies AM; Kakavand H; Wilmott JS; Hyman J; Yearley JH; Kefford RF; Thompson JF; Long GV; Hersey P; Scolyer RA
Pigment Cell Melanoma Res; 2015 May; 28(3):245-53. PubMed ID: 25477049
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
15. RAC1P29S is a spontaneously activating cancer-associated GTPase.
Davis MJ; Ha BH; Holman EC; Halaban R; Schlessinger J; Boggon TJ
Proc Natl Acad Sci U S A; 2013 Jan; 110(3):912-7. PubMed ID: 23284172
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
Mar VJ; Wong SQ; Logan A; Nguyen T; Cebon J; Kelly JW; Wolfe R; Dobrovic A; McLean C; McArthur GA
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1117-25. PubMed ID: 25043693
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic Differences of Activation of Rac1
Senyuz S; Jang H; Nussinov R; Keskin O; Gursoy A
J Phys Chem B; 2021 Apr; 125(15):3790-3802. PubMed ID: 33848152
[TBL] [Abstract][Full Text] [Related]
18. Targeting effector pathways in RAC1
Uribe-Alvarez C; Guerrero-Rodríguez SL; Rhodes J; Cannon A; Chernoff J; Araiza-Olivera D
Small GTPases; 2021 Jul; 12(4):273-281. PubMed ID: 32043900
[TBL] [Abstract][Full Text] [Related]
19. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
[TBL] [Abstract][Full Text] [Related]
20. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
Alsuliman A; Colak D; Al-Harazi O; Fitwi H; Tulbah A; Al-Tweigeri T; Al-Alwan M; Ghebeh H
Mol Cancer; 2015 Aug; 14():149. PubMed ID: 26245467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]